PMID- 22252776
OWN - NLM
STAT- MEDLINE
DCOM- 20120829
LR  - 20180802
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 141
DP  - 2011
TI  - Ex vivo expansion of hematopoietic stem cells: mission accomplished?
PG  - w13316
LID - 10.4414/smw.2011.13316 [doi]
AB  - A small number of hematopoietic stem cells (HSCs) with self-renewal and 
      multi-lineage repopulation capacity maintain hematopoiesis during the lifetime of 
      an individual. Moreover, HSCs and their potential exist in excess as one 
      individual can share its HSCs with another leading to creation of a genetically 
      identical hematopoietic system. For over half a century this property of HSCs has 
      been utilised by successful allogeneic clinical HSC transplantation for treatment 
      of patients with inherited or acquired genetic and neoplastic diseases of the 
      hematopoietic and immune system. There are now more than twenty thousand 
      allogeneic HSC transplants per year worldwide [1]. However, although more than 
      17.5 million potential HSC donors are registered and additional 500,000 cord 
      bloods are stored for potential allogeneic HSC transplantation [2], timely 
      availability of appropriately human leukocyte antigen (HLA)-compatible HSCs with 
      sufficient quality for patients still poses a problem in the field. Even if a 
      donor is available, toxicity of the procedure could be reduced by increasing HSC 
      numbers in transplants. One way to solve these issues would be by generation of 
      quality-controlled, off the shelf HSC products via in vitro HSC expansion, a 
      "holy grail" procedure many have been hunting for. Here, we discuss accumulating 
      knowledge on signalling pathways involved in HSC maintenance as well as recent 
      achievements to apply the findings to ex vivo HSC expansion for clinical use. 
      Although the specific issue concerns only highly specialised medicine today, 
      newly generated knowledge will be critical for the whole field of stem cell 
      transplantation and regenerative medicine in the future.
FAU - Takizawa, Hitoshi
AU  - Takizawa H
AD  - Division of Hematology, University Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Schanz, Urs
AU  - Schanz U
FAU - Manz, Markus G
AU  - Manz MG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111229
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Hematopoiesis
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Hematopoietic Stem Cells/*metabolism
MH  - Humans
MH  - Mice
MH  - Signal Transduction/*physiology
EDAT- 2012/01/19 06:00
MHDA- 2012/08/30 06:00
CRDT- 2012/01/19 06:00
PHST- 2012/01/19 06:00 [entrez]
PHST- 2012/01/19 06:00 [pubmed]
PHST- 2012/08/30 06:00 [medline]
AID - smw-13316 [pii]
AID - 10.4414/smw.2011.13316 [doi]
PST - epublish
SO  - Swiss Med Wkly. 2011 Dec 29;141:w13316. doi: 10.4414/smw.2011.13316. eCollection 
      2011.